Drug Class Detail

Drug Class BCL2 inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
BDA-366 BCL2 inhibitor 15 BDA-366 is a small molecule selective inhibitor of BCL2 that targets the BH4 domain and induces pro-apoptotic activity, potentially resulting in increased tumor cell apoptosis (PMID: 26004684).
Oblimersen Genasense augmerosen|G3139 BCL2 inhibitor 15 Genasense (oblimersen) is an antisense oligonucleotide that targets BCL-2, resulting in decreased protein expression, which potentially leads to increased tumor cell apoptosis (NCI Drug Dictionary).
SPC2996 BCL2 inhibitor 15 SPC2996 is an antisense oligonucleotide against BCL-2, which inhibits BCL-2 protein expression, potentially resulting in increased tumor cell death (PMID: 21358717).
Venetoclax Venclexta ABT-199|RG7601|GDC-0199 BCL2 inhibitor 15 Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).
BCL201 S55746 BCL2 inhibitor 15 BCL201 (S55746) inhibits BCL2, potentially resulting in increased tumor cell apoptosis (NCI Drug Dictionary).
HA14-1 BCL2 inhibitor 15 HA14-1 is a BCL2 antagonist, which may induce tumor cell apoptosis and increase sensitivity to chemotherapeutics (PMID: 16510597, PMID: 16213584).
PNT2258 BCL2 inhibitor 15 PNT2258 is an oligonucleotide that binds to DNA upstream of BCL-2 and prevents its transcription, potentially resulting in increased tumor cell apoptosis (PMID: 24832107).
BM-1197 BCL-XL inhibitor 9 BCL2 inhibitor 15 BM-1197 is a dual inhibitor of BCL2 and BCL-XL, which may result in increased apoptosis and decreased tumor growth (PMID: 24901320).
Disarib BCL2 inhibitor 15 Disarib is a small molecule inhibitor of BCL2, which targets the BH1 domain of BCL2, thereby interfering with the interaction between BCL2 and BAK, and subsequently, leading to apoptosis (PMID: 28223017).
ABT-737 BCL-XL inhibitor 9 BCL2 inhibitor 15 ABT-737 is a BH3 mimetic, which targets Bcl2, Bcl-xl, and Bcl-w to induce apoptosis (NCI Drug Dictionary).
S44563 BCL-XL inhibitor 9 BCL2 inhibitor 15 S44563 binds to BCL-2 and BCL-XL and inhibits their interaction with BH3, which potentially results in increased tumor cell apoptosis and decreased tumor growth (PMID: 24454684).
TW-37 BCL-XL inhibitor 9 BCL2 inhibitor 15 MCL1 Inhibitor 12 TW-37 is a third-generation BH3 mimetic that inhibits BCL2, MCL1, and with lesser affinity, BCL-XL, which may result in increased tumor cell apoptosis and increased sensitivity to chemotherapeutics (PMID: 17404107).
Navitoclax ABT-263 BCL-XL inhibitor 9 BCL2 inhibitor 15 Navitoclax (ABT-263) is a BCL2, BCL-XL, and BCL-W inhibitor, which may enhance the efficacy of chemotherapeutics (PMID: 25787766).
MRX34 BCL2 inhibitor 15 c-MYC Inhibitor 9 MET Inhibitor 50 MRX34 is a liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity through inhibition of MYC, MET, BCL2, CCND1 and CTNNB1 (NCI Drug Dictionary; PMID: 24657911).
APG-1252 BM-1252 BCL-XL inhibitor 9 BCL2 inhibitor 15 APG-1252 inhibits BCL2 and BCL-XL, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (Eur J Cancer, 2014, Vol 50 , pp.109-10).
Molecular Profile Protein Effect Treatment Approaches